During the past decade, The Cancer Institute Hospital of JFCR conducted 169 clinical trials. In the 10-year time frame, 169 clinical trials started and 70 clinical trials were completed, i.e. on average, 41.4% percent of trials that started reached the finish line to date. In the past 5 years, 87 clinical trials started and 48 clinical trials were completed. i.e. 55.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Cancer Institute Hospital of JFCR" #1 sponsor was "Hoffmann-La Roche" with 41 trials, followed by "Pfizer" with 20 trials sponsored, "Amgen" with 14 trials sponsored, "Janssen Research & Development, LLC" with 13 trials sponsored and "Daiichi Sankyo, Inc." with 13 trials sponsored. Other sponsors include 102 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Cancer Institute Hospital of JFCR" #1 collaborator was "AstraZeneca" with 16 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 7 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 4 trials as a collaborator, "Daiichi Sankyo, Inc." with 4 trials as a collaborator and "Merck Sharp & Dohme LLC" with 3 trials as a collaborator. Other collaborators include 48 different institutions and companies that were collaborators in the rest 51 trials.

According to Clinical.Site data, the most researched conditions in "The Cancer Institute Hospital of JFCR" are "Carcinoma, Non-Small-Cell Lung" (14 trials), "Breast Cancer" (9 trials), "Lymphoma, Non-Hodgkin" (9 trials), "Non-Small Cell Lung Cancer" (9 trials) and "Gastric Cancer" (7 trials). Many other conditions were trialed in "The Cancer Institute Hospital of JFCR" in a lesser frequency.

Most popular intervention types in "The Cancer Institute Hospital of JFCR" are "Drug" (198 trials), "Other" (14 trials), "Biological" (10 trials), "Radiation" (6 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Carboplatin" (24 trials), "Atezolizumab" (22 trials), "Cisplatin" (18 trials) and "Paclitaxel" (17 trials). Other intervention names were less common.

The vast majority of trials in "The Cancer Institute Hospital of JFCR" are 188 trials for "All" genders, 15 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "The Cancer Institute Hospital of JFCR". undefined are not yet recruiting, 54 are recruiting, 71 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 67 completed trials in The Cancer Institute Hospital of JFCR, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in The Cancer Institute Hospital of JFCR, 48 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 111 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".